Tsai Hsiu-Hui, Hsiao Fu-Chih, Yu Alice L, Juang Jyuhn-Huarng, Yu John, Chu Pao-Hsien
Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Stem Cell Rev Rep. 2025 Apr;21(3):849-858. doi: 10.1007/s12015-024-10839-8. Epub 2025 Jan 22.
Human-induced pluripotent stem cell (hiPSC) technology has been applied in pathogenesis studies, drug screening, tissue engineering, and stem cell therapy, and patient-specific hiPSC-derived cardiomyocytes (hiPSC-CMs) have shown promise in disease modeling, including diabetic cardiomyopathy. High glucose (HG) treatment induces lipotoxicity in hiPSC-CMs, as evidenced by changes in cell size, beating rate, calcium handling, and lipid accumulation. Empagliflozin, an SGLT2 inhibitor, effectively mitigates the hypertrophic changes, abnormal calcium handling, and contractility impairment induced by HG. Glucose concentration influences SGLT2 expression in cardiomyocytes, highlighting its potential role in diabetic cardiomyopathy. These findings support the potential utility of hiPSC-CMs in studying diabetic cardiomyopathy and the efficacy of empagliflozin in ameliorating HG-induced cardiomyocyte dysfunction. Such research may advance developments in precision medicine and therapeutic interventions for patients with diabetic cardiomyopathy.
人诱导多能干细胞（hiPSC）技术已应用于发病机制研究、药物筛选、组织工程和干细胞治疗，且患者特异性的hiPSC衍生心肌细胞（hiPSC-CMs）在包括糖尿病性心肌病在内的疾病建模中显示出前景。高糖（HG）处理会在hiPSC-CMs中诱导脂毒性，细胞大小、搏动率、钙处理和脂质积累的变化证明了这一点。恩格列净，一种SGLT2抑制剂，可有效减轻HG诱导的肥大变化、异常钙处理和收缩功能障碍。葡萄糖浓度会影响心肌细胞中SGLT2的表达，突出了其在糖尿病性心肌病中的潜在作用。这些发现支持了hiPSC-CMs在研究糖尿病性心肌病中的潜在效用以及恩格列净改善HG诱导的心肌细胞功能障碍的疗效。此类研究可能会推动糖尿病性心肌病患者精准医学和治疗干预的发展。
